EN DE
STOCK COMPARISON

IDEXX Laboratories vs Thermo Fisher Scientific: Fair Value & Quality

Both stocks run through our valuation models. Here is how IDEXX Laboratories (IDXX) and Thermo Fisher Scientific (TMO) compare, as of Aug 14, 2026.

As of Aug 14, 2026, Fair Value Calculator sees Thermo Fisher Scientific as the less overvalued of the two: IDEXX Laboratories trades at $567 versus a fair value of $256 (-55%), while Thermo Fisher Scientific trades at $596 versus $308 (-48%).
IDEXX Laboratories
IDXX · USD · Health Care
-55%
upside to fair value
overvalued
Price$567
Fair Value$256
Quality85/100
Thermo Fisher Scientific
TMO · USD · Health Care
-48%
upside to fair value
overvalued
Price$596
Fair Value$308
Quality63/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

IDEXX LaboratoriesThermo Fisher Scientific
Valuation
41.1×P/E (TTM)29.5×
10.22×P/S (TTM)4.41×
28.31×P/B3.74×
29.5×EV/EBITDA20.0×
3.57×PEG1.74×
Dividend yield0.3%
Dividend per share$1.76
Profitability
25%Net margin15%
32%Operating margin18%
73%Return on equity14%
26%Return on assets5%
Growth
14%Revenue growth (YoY)6%
8.5%Avg. growth/yr (3Y)-0.3%
9.7%Avg. growth/yr (5Y)6.7%
Balance & size
0.23×Debt / equity0.67×
$45BMarket cap$199B
healthyGrowth qualityhealthy

IDEXX Laboratories leads: 8 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

IDEXX Laboratoriesof which business quality 81 · market factors 32 Thermo Fisher Scientificof which business quality 60 · market factors 68
ProfitabilityMargins and returns on capital today
99
43
Quality GrowthAre margins and returns improving?
74
31
CashflowEarnings quality: real cash, not paper profit
81
62
Fin. StrengthBalance sheet, leverage, solvency risk
72
60
InvestmentDisciplined investing over empire-building
54
79
Low VolatilityCalm price path (market factor)
42
69
MomentumPrice trend over the last 3–12 months (market factor)
33
65
52W MomentumDistance to the 52-week high (market factor)
20
71
Net IssuanceBuybacks instead of dilution
99
97

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

IDEXX Laboratories

DCF Models$296
Earnings-Based$148
Dividend Discount$10.39
Multiples$228
Asset-Based$13.64
Growth DCF$249
Economic Profit$264
Growth Earnings$248

26 of 26 models see the stock below the current price.

Thermo Fisher Scientific

DCF Models$354
Earnings-Based$203
Multiples$308
Asset-Based$96.29
Growth DCF$288
Economic Profit$159
Growth Earnings$341

24 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

IDEXX Laboratories
Bear $155Fair Value $256Bull $323
$567 = current price (white tick)
Thermo Fisher Scientific
Bear $171Fair Value $308Bull $385
$596 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

IDEXX Laboratories · Health Care

Quality score85 · Top 25%
Fair value upside-55% · below median

Thermo Fisher Scientific · Health Care

Quality score63 · Top 25%
Fair value upside-48% · below median

Bottom line

As of Aug 14, 2026, Fair Value Calculator sees Thermo Fisher Scientific as the less overvalued of the two: IDEXX Laboratories trades at $567 versus a fair value of $256 (-55%), while Thermo Fisher Scientific trades at $596 versus $308 (-48%).

IDEXX Laboratories has the higher quality score (85/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.